Rapid Improvement in Atopic Dermatitis With Dual JAK/TYK2 Inhibitor

[ad_1]

(MedPage Today) — ORLANDO — More than 80% of patients with moderate or severe atopic dermatitis (AD) had at least 75% improvement after 12 weeks of treatment with an investigational dual-target small-molecule inhibitor, according to a study…

[ad_2]

Source link : https://www.medpagetoday.com/meetingcoverage/aad/114634

Author :

Publish date : 2025-03-13 16:28:00

Copyright for syndicated content belongs to the linked Source.